MarketPulse

biotech investment

11 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

RTW Investments Bets $193M on Apellis Rebound Despite 29% Stock Decline

RTW Investments establishes $193M position in Apellis Pharmaceuticals despite 29% stock decline, betting on turnaround potential of $689M revenue-generating biotech.
ARGXAPLSMDGLINSMinstitutional investmentbiotech investment
The Motley FoolThe Motley Fool··Jonathan Ponciano

RTW's $116M Cogent Bet Amplifies Biotech Rally Ahead of Key FDA Decision

RTW Investments purchases $116M stake in Cogent Biosciences, raising position to 2.7% of AUM amid 360% stock surge and anticipated 2026 FDA decision on lead drug.
COGTFDA approvalinstitutional investment
The Motley FoolThe Motley Fool··Seena Hassouna

ENAVATE's Zenas Stake Surge Masks Real Story: Obexelimab Pipeline

ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.
ZBIOFDA approvalautoimmune diseases
The Motley FoolThe Motley Fool··Andy Gould

Swiss Biotech Fund Doubles Down on Relay With $6M Stake Bet

Swiss biotech fund Nextech Invest increases Relay Therapeutics stake by $6.1M, signaling institutional confidence in company's computational platform and clinical pipeline.
RVMDRVMDWRLAYXBIIBBinstitutional buyingbiotech investment
The Motley FoolThe Motley Fool··Seena Hassouna

Specialist Biotech Fund's $25.8M Spyre Bet Signals Confidence in Preclinical Pipeline

VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.
SYREbiotech investmentmonoclonal antibodies
The Motley FoolThe Motley Fool··Jonathan Ponciano

Oncology Biotech Syndax Surges on $6.5M Investment Amid 629% Revenue Spike

Syndax Pharmaceuticals attracted $6.54M institutional investment as its approved cancer therapies generated $172.4M revenue, up 629% year-over-year, driving 80%+ stock surge.
SNDXrevenue growthcancer treatment
The Motley FoolThe Motley Fool··Jonathan Ponciano

BVF's $52M Stake in Disc Medicine Signals Confidence Despite Regulatory Hurdles

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.
KYMRRVMDRVMDWIRONFDA approvalclinical trial
The Motley FoolThe Motley Fool··Jonathan Ponciano

Perceptive Advisors Doubles Down on Praxis, Stock Rallies 320%

Perceptive Advisors doubles investment in Praxis Precision Medicines to $588M, now largest holding. Stock surges 320% amid FDA submissions and strong cash position.
PRAXFDA approvalinstitutional investment
The Motley FoolThe Motley Fool··Jonathan Ponciano

Redmile Group Doubles Down on Nurix With $63M Investment Despite Underperformance

Redmile Group adds $63M to Nurix stake despite stock decline, betting on promising BTK degrader clinical data and upcoming registrational trials.
NRIXKRYSstock underperformanceclinical trial
The Motley FoolThe Motley Fool··Jonathan Ponciano

First Turn Management Establishes $35M Stake in Clinical-Stage Biotech Terns

First Turn Management invests $35M in clinical-stage biotech Terns Pharmaceuticals, acquiring 4.03% stake. Stock surged 826% year-over-year on cancer drug trial progress.
TERNdrug developmentstock surge
The Motley FoolThe Motley Fool··Lawrence Rothman, Cfa

Soleus Capital Elevates Celcuity to Third-Largest Position With Major Share Purchase

Soleus Capital significantly increased its Celcuity stake to 1.8 million shares, making it their third-largest position worth $180 million as the biotech stock surged 745% yearly.
PRAXCELCKRYSNVCRportfolio allocationinstitutional buying